The type of bladder cancer previously had limited FDA-approved therapies available to treat it, according to Scot Ebbinghaus, MD, vice president of clinical research at Merck. Patients traditionally have had limited nonsurgical options to treat the aggressive form of cancer.
Keytruda works by increasing the immune system’s ability to help detect and fight tumor cells. It has been approved to treat a number of other cancers, including lung cancer and melanoma.
Merck warned that inflammatory reactions, which could be severe or fatal, can occur with Keytruda, and it can also cause severe or life-threatening infusion-related reactions.
Read the full news release here.
More articles on pharmacy:
California governor to announce state-run generic drug company
Celgene backs out of $55M drug monopoly settlement
CVS, Walgreens sue Ohio physicians, claim they share blame for opioid crisis
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.